Search Results - "Selvaggi, Giovanni"

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451 by Owonikoko, Taofeek K, Park, Keunchil, Govindan, Ramaswamy, Ready, Neal, Reck, Martin, Peters, Solange, Dakhil, Shaker R, Navarro, Alejandro, Rodríguez-Cid, Jerónimo, Schenker, Michael, Lee, Jong-Seok, Gutierrez, Vanesa, Percent, Ivor, Morgensztern, Daniel, Barrios, Carlos H, Greillier, Laurent, Baka, Sofia, Patel, Miten, Lin, Wen Hong, Selvaggi, Giovanni, Baudelet, Christine, Baden, Jonathan, Pandya, Dimple, Doshi, Parul, Kim, Hye Ryun

“…In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability…”
Get full text

Targeting ALK Rearrangements in NSCLC: Current State of the Art by Peng, Ling, Zhu, Liping, Sun, Yilan, Stebbing, Justin, Selvaggi, Giovanni, Zhang, Yongchang, Yu, Zhentao

“…Anaplastic lymphoma kinase (ALK) alterations in non-small cell lung cancer (NSCLC) can be effectively treated with a variety of ALK-targeted drugs. After the…”
Get full text

1527 ENB-003, an ETBR antagonist, in combination with pembrolizumab, shows promise in microsatellite stable platinum refractory/resistant ovarian cancer: data from the ENBOLDEN-101 phase 1B study by Jamal, Sumayah, Selvaggi, Giovanni

“…BackgroundEndothelin B receptor (ETBR) expression in ovarian cancer is associated with a poor prognosis and tumors that lack tumor infiltrating lymphocytes.1…”
Get full text

Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy by RIGHI, Luisella, PAPOTTI, Mauro G, CEPPI, Paolo, BILLE, Andrea, BACILLO, Elisa, MOLINARO, Luca, RUFFINI, Enrico, SCAGLIOTTI, Giorgio V, SELVAGGI, Giovanni

“…The relationship between thymidylate synthase (TS) expression and outcome in patients with malignant pleural mesothelioma (MPM) treated with pemetrexed (P) was…”
Get full text

Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors by Bagegni, Nusayba A., Park, Haeseong, Kraft, Katlyn, O-Toole, Maura, Gao, Feng, Waqar, Saiama N., Ratner, Lee, Morgensztern, Daniel, Devarakonda, Siddhartha, Amin, Manik, Baggstrom, Maria Q., Liang, Chris, Selvaggi, Giovanni, Wang-Gillam, Andrea

“…Purpose Vorolanib is a multi-target tyrosine kinase inhibitor with anti-angiogenic properties. This study aimed to evaluate the tolerability, safety and…”
Get full text

Efficacy and Safety of First-Line Treatment Strategies for Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Bayesian Network Meta-Analysis by Peng, Ling, Lu, Dafeng, Xia, Yang, Hong, Shaodong, Selvaggi, Giovanni, Stebbing, Justin, Sun, Yilan, Liang, Fei

“…Targeted therapies have led to significant improvement in the management and prognosis of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer…”
Get full text

The Biology of Epidermal Growth Factor Receptor in Lung Cancer by SCAGLIOTTI, Giorgio V, SELVAGGI, Giovanni, NOVELLO, Silvia, HIRSCH, Fred R

“…The prognostic significance of epidermal growth factor receptor (EGFR) expression in lung cancer and, more importantly, its ability to predict response to…”
Get full text

Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma by Zalcman, Gerard, Peters, Solange, Mansfield, Aaron Scott, Jahan, Thierry Marie, Popat, Sanjay, Scherpereel, Arnaud, Hu, Wenhua, Selvaggi, Giovanni, Baas, Paul

“…Abstract only TPS8581 Background: Malignant pleural mesothelioma (MPM) is an aggressive cancer with a 5-year overall survival (OS) rate of < 10%. At diagnosis,…”
Get full text

730 A phase I safety and tolerability study of VAXinia (CF33-hNIS), a novel chimeric oncolytic poxvirus, administered intratumorally or intravenously in adults with metastatic or advanced solid tumors by Li, Daneng, Spira, Alexander I, Mamdani, Hirva, Leddon, Jennifer, Fong, Yuman, Chong, Leslie, Fein, Seymour, Ede, Nick, McCurry, Ursula, Seiz, Amanda, Polasek, Melissa, Yavrom, Sharon, Selvaggi, Giovanni

“…BackgroundCF33 is a novel chimeric oncolytic poxvirus, encoding the human Sodium-Iodide Symporter (hNIS) transgene. The transgene is inserted in place of the…”
Get full text

Prospective Assessment of XPD Lys751Gln and XRCC1 Arg399Gln Single Nucleotide Polymorphisms in Lung Cancer by GIACHINO, Daniela F, GHIO, Paolo, REGAZZONI, Silvia, MANDRILE, Giorgia, NOVELLO, Silvia, SELVAGGI, Giovanni, GREGORI, Dario, DEMARCHI, Mario, SCAGLIOTTI, Giorgio V

“…Purpose: XRCC1 and XPD play key roles in the repair of DNA lesions and adducts. Contrasting findings have been reported on the effect of polymorphisms of these…”
Get full text

A Phase 1/2 Study to Evaluate the Safety and Activity of Nivolumab in Combination With Vorolanib, a Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor, in Patients With Refractory Thoracic Tumors by Beckermann, Kathryn E., Bestvina, Christine M., El Osta, Badi, Sanborn, Rachel E., Borghaei, Hossein, Lammers, Philip Edward, Selvaggi, Giovanni, Whisenant, Jennifer G., Heimann-Nichols, Ellen, Berry, Lynne, Hsu, Chih-Yuan, Shyr, Yu, Horn, Leora, Wakelee, Heather

“…Targeting the tumor microenvironment may enhance response to immunotherapy (immune checkpoint inhibitors) and improve outcomes for patients. This study tested…”
Get full text

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study by Zheng, Jing, Wang, Tao, Yang, Yunpeng, Huang, Jie, Feng, Jifeng, Zhuang, Wu, Chen, Jianhua, Zhao, Jun, Zhong, Wei, Zhao, Yanqiu, Zhang, Yiping, Song, Yong, Hu, Yi, Yu, Zhuang, Gong, Youling, Chen, Yuan, Ye, Feng, Zhang, Shucai, Cao, Lejie, Fan, Yun, Wu, Gang, Guo, Yubiao, Zhou, Chengzhi, Ma, Kewei, Fang, Jian, Feng, Weineng, Liu, Yunpeng, Zheng, Zhendong, Li, Gaofeng, Wang, Huijie, Cang, Shundong, Wu, Ning, Song, Wei, Liu, Xiaoqing, Zhao, Shijun, Ding, Lieming, Selvaggi, Giovanni, Wang, Yang, Xiao, Shanshan, Wang, Qian, Shen, Zhilin, Zhou, Jianya, Zhou, Jianying, Zhang, Li

“…Background The initial phase II stuty (NCT03215693) demonstrated that ensartinib has shown clinical activity in patients with advanced crizotinib‐refractory,…”
Get full text

Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial by SCAGLIOTTI, Giorgio V, KORTSIK, Cornelius, NOVELLO, Silvia, BLATTER, Johannes, KAYITALIRE, Louis, CRINO, Lucio, PAZ-ARES, Luis, DARK, Graham G, PRICE, Allan, MANEGOLD, Christian, ROSELL, Rafael, O'BRIEN, Mary, PETERSON, Patrick M, CASTELLANO, Daniel, SELVAGGI, Giovanni

“…Purpose: To determine efficacy and toxicity of two pemetrexed-based regimens in chemonaive patients with locally advanced or metastatic non–small cell lung…”
Get full text

Advances in diagnosis and treatment of malignant pleural mesothelioma by Giorgio Vittorio Scagliotti, Giovanni Selvaggi

“…Malignant pleural mesothelioma (MPM) is an aggressive but relatively rare malignancy with median survival ranging from 8 to 14 months depending on stage and…”
Get full text

Advances in diagnosis and treatment of malignant pleural mesothelioma by Giorgio Vittorio Scagliotti, Giovanni Selvaggi

“…Malignant pleural mesothelioma (MPM) is an aggressive but relatively rare malignancy with median survival ranging from 8 to 14 months depending on stage and…”
Get full text

Gemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II Trial by CRINO, L, MOSCONI, A. M, DE MARINIS, F, NOSEDA, M, TONATO, M, SCAGLIOTTI, G, SELVAGGI, G, NOVELLO, S, RINALDI, M, DELLA GIULIA, M, GRIDELLI, C, ROSSI, A, CALANDRI, C

“…To investigate the activity and toxicity of gemcitabine as a single agent in patients with advanced non-small-cell lung cancer (NSCLC) after recurrence or…”
Get full text

A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC) by Concannon, Kyle, Selvaggi, Giovanni, Zhou, Joey, Elamin, Yasir Y

“…8624 Background: Ensartinib is an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), which has shown systemic and central nervous system…”
Get full text

Prognostic Role of Protease-Activated Receptors 1 and 4 in Resected Stage IB Non-Small-Cell Lung Cancer by Ghio, Paulo, Cappia, Susanna, Selvaggi, Giovanni, Novello, Sylvia, Lausi, Paulo, Zecchina, Gabriella, Papotti, Marno, Borasio, Piero, Scagliotti, Giorgio V.

“…Protease-activated receptor (PAR)-1 and PAR-4 are involved in extracellular matrix invasion and angiogenesis. A series of 60 resected stage IB non-small-cell…”
Get full text

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer by Hellmann, Matthew D., Callahan, Margaret K., Awad, Mark M., Calvo, Emiliano, Ascierto, Paolo A., Atmaca, Akin, Rizvi, Naiyer A., Hirsch, Fred R., Selvaggi, Giovanni, Szustakowski, Joseph D., Sasson, Ariella, Golhar, Ryan, Vitazka, Patrik, Chang, Han, Geese, William J., Antonia, Scott J.

“…Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers…”
Get full text

A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma by Mahalingam, Devalingam, Fountzilas, Christos, Moseley, Jennifer, Noronha, Nicole, Tran, Hue, Chakrabarty, Romit, Selvaggi, Giovanni, Coffey, Matthew, Thompson, Brad, Sarantopoulos, John

“…REOLYSIN ® (pelareorep) is an investigational new drug, consisting of a live, replication-competent, Reovirus Type 3 Dearing strain in a proprietary…”
Get full text